Plain-English translation of NCT06746701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing peginterferon alpha-2b combined with nucleoside analogues to see if this two-drug combination can prevent liver cancer better than taking just one medication alone. The study will follow 400 people with chronic hepatitis B who have a family history of liver cancer for up to 5 years. Researchers want to understand whether this medication combination is safe, effective, and can truly reduce the chance of developing liver cancer.
People with hepatitis B and a family history of liver cancer are at especially high risk for developing the disease. Doctors want to know if using this medication combination instead of a single drug could offer better protection against liver cancer and cure the virus more effectively.
You likely qualify if…
You likely don't qualify if…
You will be assigned to either the combination treatment group or the single medication group based on your doctor's recommendation and your choice. You will receive injections or pills as prescribed by the research team according to standard treatment guidelines. Throughout the study, you'll have regular check-ins and blood tests to monitor how well the treatment is working and to watch for any side effects, with follow-up visits continuing for up to 5 years.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China